Does Rallies show CLRB 10-K and 10-Q filings?

Rallies organizes CLRB SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.

Is CLRB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CLRB. It does not provide personalized investment advice.

CLRB (Cellectar Biosciences INC NEW) Stock Analysis - SEC Filings

Cellectar Biosciences INC NEW (CLRB) is a publicly traded Healthcare sector company. As of May 21, 2026, CLRB trades at $3.10 with a market cap of $25.09M and a P/E ratio of -0.38. CLRB moved +3.43% today. Year to date, CLRB is -5.37%; over the trailing twelve months it is -59.97%. Its 52-week range spans $2.43 to $67.50. Analyst consensus is strong buy with an average price target of $10.33. Rallies surfaces CLRB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find CLRB SEC filings?

Rallies organizes CLRB SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

CLRB Key Metrics

Key financial metrics for CLRB
Metric	Value
Price	$3.10
Market Cap	$25.09M
P/E Ratio	-0.38
EPS	$-8.35
Dividend Yield	0.00%
52-Week High	$67.50
52-Week Low	$2.43
Volume	2.25K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-21.79M
Gross Margin	0.00%

Latest CLRB News

Cellectar Biosciences Secures $140M, Posts 61.8% MRR and 83.6% ORR — May 14, 2026
Cellectar Biosciences YTD Gain 19.7% and 59.3% EPS Estimate Increase, Q1 Call Scheduled — May 11, 2026
Cellectar Biosciences Reports 83.6% ORR, 61.8% MRR and Raises $140M — May 5, 2026
Cellectar Biosciences Reports $21.8M Loss, Eyes EU Filing in Q3 2026 — Mar 4, 2026
Cellectar Biosciences Secures New Patents in Europe, Asia-Pacific, Middle East and Americas Ahead of 3Q26 EMA Filing — Feb 17, 2026

Recent CLRB Insider Trades

Longcor Jarrod bought 8.68K (~$25.00K) on May 7, 2026.
CARUSO JAMES V bought 8.68K (~$25.00K) on May 7, 2026.
NEIS JOHN sold 198 (~$731.986) on Dec 12, 2025.

CLRB Analyst Consensus

3 analysts cover CLRB: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.33.

Common questions about CLRB

Where can I find CLRB SEC filings?: Rallies organizes CLRB SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show CLRB 10-K and 10-Q filings?: Rallies organizes CLRB SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is CLRB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CLRB. It does not provide personalized investment advice.